#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related: